RAINBOW CHILDREN'S MEDICARE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,403 INR | +0.22% |
|
-4.14% | +17.63% |
| 03-18 | Rainbow Children's Medicare Limited Approves Appointment of Adarsh Kancharla as Non-Executive Director | CI |
| 03-08 | Rainbow Children's Medicare Expands Capacity of Hyderabad, India Hospital | MT |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 61% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 63.15 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +17.63% | 1.7B | C- | ||
| -18.90% | 16.72B | B+ | ||
| +4.50% | 12.64B | B | ||
| +4.81% | 11.7B | B+ | ||
| +2.43% | 10B | B+ | ||
| +29.69% | 8.7B | B | ||
| -4.75% | 7.6B | A- | ||
| +21.11% | 7.22B | D | ||
| +5.46% | 6.65B | B- | ||
| +45.72% | 4.5B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- RAINBOW Stock
- Ratings Rainbow Children's Medicare Limited
